Medtronic announces intent to separate Diabetes business

Go back to Medtronic announces intent to separate Diabetes business

Evercore ISI Removes Medtronic, Inc. (MDT) from TAP List

May 21, 2025 4:52 PM EDT

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $103.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "Heading into earnings, we had TAP (tactical, actionable, positioning) calls on A, DHR, ENOV, MDT, SYK, TMO, & RVTY (previous tap note... More

Medtronic, Inc. (MDT) PT Lowered to $98 at Citi

May 21, 2025 2:08 PM EDT

Citi analyst Joanna Wuensch lowered the price target on Medtronic, Inc. (NYSE: MDT) to $98.00 (from $103.00) while maintaining a Buy rating.

The analyst comments "This was a quarterly report where many things seemed to go right for Medtronic: 1) FY4Q25 revenue $8.93B (up 5.4% y/y... More